Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT151 in Advanced Solid Tumors
NCT04455620Phase 2Terminated
- Sponsor
- BioNTech SE
- Start
- Jan 2021
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of ribocytokine IL-2 BNT151 in solid tumor, sponsored by BioNTech SE. Started Jan 2021; status: terminated.
02
Drugs
ribocytokine IL-2 BNT151
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04455620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04455620.